Azer-cel for autoimmune disorders like MS, NMOSD, MG, and CIDP
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This trial tests an investigational cell therapy called Azer-cel in people with certain autoimmune diseases that affect the nerves or muscles. It aims to see if the treatment is safe and can help reduce symptoms by targeting the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old, depending on the specific disease group.
- You need a confirmed diagnosis of one of these conditions: multiple sclerosis (certain progressive or relapsing types), neuromyelitis optica spectrum disorder, generalized myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy.
- You must have a certain level of disability, measured by standard scales like EDSS or MG-ADL, that qualifies for the study.
- You cannot have had prior treatment with CAR T-cell therapy or similar gene therapies.
- You must not have active hepatitis B, HIV, or a history of certain cancers in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This early-stage trial tests a new CAR-T cell therapy called HY001N for people with hard-to-treat neurological autoimmune diseases like NMOSD, myasthenia gravis, MS, and others. It aims to see if targeting B cells can help when standard treatments have failed.
Hear when a new B-cell Mediated Autoimmune Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.